90 results about "Excessive Bleeding" patented technology

Described herein are compositions and methods related to wound treatment. Compositions are multi-components admixed in amounts and ratios to meet specific objectives for optimally treating various types of wound injury.

The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (e.g. human Factor VIIa) and a buffering agent; wherein the molar ratio of non-complexed calcium ions (Ca²⁺) to the Factor VII polypeptide is lower than 0.5. The composition may further comprise a stabilizing agent (e.g. copper or magnesium ions, benzamidine, or guanidine), a non-ionic surfactant, a tonicity modifying agent, an antioxidant and a preservative. The composition is useful for treating a Factor VII-responsive syndrome, such as bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor XI deficiency, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy.

A method and system for use in the course of extracorporeal blood flow, e.g., cardiopulmonary bypass, dialysis, and angioplasty procedures, in order to reduce or minimize inflammation, excessive bleeding, and other undesirable side effects. The system can include one or more automated blood parameter sensor modules and one or more blood parameter regulating modules. The system is particularly well suited to monitor and/or regulate blood parameters that include blood analytes (e.g., biomolecules, drugs or metabolites) as well as blood functions (e.g., clotting time, fibrinolytic activity, immune response). The system is particularly well suited for use in the management of clotting (e.g., heparing/protamine) and bleeding (e.g., aprotinin).

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents. One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

A method for producing an aqueous polyurethane synthetic leather is as below: impregnating a fabric by using a mixed liquid of calcium formate and calcium chloride, drying the rolling liquid to obtain a pretreated fabric; adding a foam coagulant, calcium formate and pigment in the aqueous polyurethane, mixing evenly to obtain an aqueous polyurethane slurry; scraping the slurry on the pretreated aqueous polyurethane fabric to obtain an aqueous polyurethane synthetic leather base; and subjecting the aqueous polyurethane synthetic leather base to aqueous surface treatment and vacuum line suction to obtain the aqueous polyurethane synthetic leather. The method employs a mixed liquid of calcium formate and calcium chloride for impregnating treatment on the fabric, so as to prevent excessive bleeding of the slurry in the adhesive layer into the fabric and influence on the handle feel of the synthetic leather; the aqueous surface treatment and vacuum line suction post-finishing process endow the aqueous polyurethane synthetic leather with good handle feel and mechanical properties. The present invention uses environmentally friendly materials and clean production process; and the obtained synthetic leather has content of any solvent less than 5ppm, and meets the requirements of ecological synthetic leather.

A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.

The present invention provides methods of using recombinant human fibrinogen to prevent or treat excessive bleeding in pre-hospital and hospital settings. In particular, the present invention relates to methods for treating bleeding using recombinant human fibrinogen in individuals suffering from traumatic hemorrhages in pre-hospital settings and in individuals having thrombocytopenia or qualitative platelet disorders.

Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidyl serine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

Tunnel bone grafting according to the proposed method can be used when an individual has a facial bone defect due to periodontal disease, cleft palate or trauma. The proposed method can be utilized for implant placement, it reduces wrinkles and supports facial muscle in order to make the individual look younger. The method can also be used to create a thicker alveolar ridge in order to stabilize full dentures or partial dentures. Its advantages over conventional guided bone regeneration techniques is that the proposed method is minimally invasive and lessens trauma to patients, prevents soft tissue opening, and reduces surgery time. Specifically, it minimizes the incision size and thus reduces trauma to the patient. Further, this reduces the risk of complications, including excessive bleeding, due to the minimization of the incision size. There is also considerable reduction in post surgery swelling using the proposed method as opposed to conventional techniques.

The invention discloses a poultry beak treatment device, and relates to the improvement of the poultry beak treatment device structure. The invention provides the poultry beak treatment device which can reduce harmful stimulation to chickens and avoid dying caused by excessive bleeding after the beak breaks, and is high in beak breaking efficiency and accurate in beak breaking. The poultry beak treatment device comprises a base, and is characterized in that an electric push rod is arranged on the base, the end part of the electric push rod is provided with a heating source, a chicken fixing device is arranged corresponding to the heating source, the chicken fixing device is provided with a first groove corresponding to the shape of the chicken head, and a beak hole corresponding to the heating source is arranged in the first groove.

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired. Administration of RMP prepared according to the invention demonstrates effectiveness in safely reducing bleeding.

The invention relates to the field of tree seedling grafting, in particular to a method for grafting an apricot tree to a peach tree. Before grafting, rootstocks are watered and disinfected, and are coated with a healing agent, so that damage to scions caused by excessive bleeding sap of the rootstocks is avoided; in addition, after grafting, temperature and humidity are timely controlled, and grafted parts are banded, so that the survival rate after grafting is greatly increased; moreover, the method is simple, convenient, high in survival rate and surviving speed and easy to popularize.

A method for remotely determining a patient's excessive bleeding tendency and a patient's resistance to blood thinning medication is disclosed. An incision is made in the patient's forearm. Blood oozing out of the incision is absorbed into a blotter paper until the bleeding stops. Blotches of blood formed on the blotter paper are captured as an image and sent to a service provider who calculates a value associated with the bleeding volume of the patient. The service provider retransmits a value associated with the bleeding volume back to the medical professional. To determine the resistance to blood thinning medication, one incision is made in the patient prior to administration of blood thinning medication. Blood oozing out of the incision is collected on blotter paper until the patient stops bleeding. A second incision is made in the patient. A second set of blotter paper is used to collect the blood oozing out of the incision until the bleeding stops. Both sets of blotter paper are sent to a service provider to calculate a value associated with the difference in bleeding volume. The service provider then retransmits the value associated with the difference in bleeding volume to the medical professional.

The present invention relates to an aqueous liquid pharmaceutical composition comprising a factor VII polypeptide (eg human factor VIIa) and a buffer; wherein the molar concentration ratio of uncomplexed calcium ions (Ca2+) to factor VII polypeptide is less than 0.5. The composition may further include stabilizers (such as copper or magnesium ions, benzamidine or guanidine), nonionic surfactants, tonicity regulators, antioxidants and preservatives. The composition is useful in the treatment of factor VII-responsive syndromes, such as bleeding disorders, including: those disorders resulting from deficiencies of clotting factors (e.g., hemophilia A, hemophilia B, factor XI deficiency, factor VII deficiency), thrombocytopenia or Willebrand disease or bleeding disorders due to clotting factor inhibitors; and intracerebral hemorrhage or excessive bleeding from any cause. These formulations may also be administered to patients in conjunction with surgery or other trauma therapy or to patients receiving anticoagulant therapy.

The invention relates to a medical device, and in particular discloses a wart cutting device for dermatology. It includes scissors. The two handles and the knife body of the scissors are both hollow structures. There is a baffle on the outside of the knife body. A connecting rod is hinged on the knife body. There is a spring piece, the free end of the spring piece leans against the connecting rod and can slide on the connecting rod; there is an arc-shaped spring piece inside the handle, and the other end of the arc-shaped spring piece extends into the handle and connects to the piston. An injection hole is provided, and several extrusion holes are arranged at the front end of the cutter body, and the extrusion holes and arc-shaped grooves are arranged on both sides of the front end of the cutter body. The present invention clamps the wart body through the arc-shaped groove during use, and the knife body continues to close to cut off the wart body, and at the same time, the hemostatic agent is squeezed out from the extrusion hole. During the operation, it can prevent secondary pollution of the cut wart body, and at the same time, apply the hemostatic agent to the wound site in time to avoid a large amount of bleeding.